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On autopsy, a patient is found to have hypertrophic cardiomyopathy. The patient’s family pursues ge-
netic testing that shows a “likely pathogenic” variant for the condition on the basis of a study in an 
original research publication. Given the dominant inheritance of the condition and the risk of sudden 
cardiac death, other family members are tested for the genetic variant to determine their risk. Several 
family members test negative and are told that they are not at risk for hypertrophic cardiomyopathy 
and sudden cardiac death, and those who test positive are told that they need to be regularly monitored 
for cardiomyopathy on echocardiography. Five years later, during a routine clinic visit of one of the 
genotype-positive family members, the cardiologist queries a database for current knowledge on the 
genetic variant and discovers that the variant is now interpreted as “likely benign” by another labora-
tory that uses more recently derived population-frequency data. A newly available testing panel for 
additional genes that are implicated in hypertrophic cardiomyopathy is initiated on an affected family 
member, and a different variant is found that is determined to be pathogenic. Family members are 
retested, and one member who previously tested negative is now found to be positive for this new vari-
ant. An immediate clinical workup detects evidence of cardiomyopathy, and an intracardiac defibril-
lator is implanted to reduce the risk of sudden cardiac death.
During the past 25 years, major advances in de-
ciphering the genetic bases of human disease 
have been achieved, and more than 5000 mende-
lian disorders are now understood at the genetic 
level.1 Although this is an extraordinarily impor-
tant achievement in our understanding of the 
biologic features of human disease, the integra-
tion of these findings into clinical care is se-
verely challenged by a lack of publicly available 
and accurate interpretations of the vast amount 
of human genetic variation known to exist. More 
than 80 million genetic variants have been un-
covered in the human genome,2 and for the 
majority, we have no clear understanding of 
their role in human health and disease. Thus, we 
are very far from a world in which we can se-
quence patients’ genomes and easily interpret 
their risk of disease, even if patients carry a vari-
ant in a gene that is associated with a highly 
penetrant genetic disorder. The rarity of most 
variants that are identified in mendelian genes 
(Fig. 1) has made it difficult to decipher the ef-
fect of such variants on gene function; most rare 
variants are labeled a “variant of uncertain sig-
nificance.” A final factor contributing to our 
lack of consistent, clear, and clinically relevant 
annotation of human genetic variation is the so-
called silo effect, in which various commercial 
and academic entities maintain isolated, some-
times proprietary, databases of variant interpre-
tations, thus preventing the sharing of critical 
knowledge that could benefit patients, families, 
health care providers, diagnostic laboratories, 
and payers.
On the basis of an analysis of submissions to 
the ClinVar variant database of the National Cen-
ter for Biotechnology Information (NCBI),3 we 
have discovered that the interpretation of the 
importance of the same variant by multiple 
clinical laboratories may differ, so that at least 
one interpretation must be wrong and could 
therefore lead to inappropriate medical interven-
tion, as illustrated in the above example. Healthy 
competition among isolated entities is no longer 
sufficient to drive our understanding of human 
variation, and patient care may be compromised 
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when data are not shared. If society is to under-
stand human genomic variation and reap its 
benefits in clinical care, large collaborative ef-
forts will be the only way to amass sufficient data 
and distribute responsibility for critical review.
In the past few years, collaborative efforts 
have shown the effectiveness of submitting data 
to public databases to advance genetic discovery. 
For example, the current human reference se-
quence would not have been possible if public 
release of data had not been encouraged.4 Simi-
larly, the replication that is critical to validate 
genomewide association studies5 depended on 
access to data from larger and larger cohorts to 
identify rarer and rarer alleles (or common al-
leles with smaller effect sizes). The field benefit-
ed tremendously from a culture of data sharing, 
and today genetic loci for more than 300 com-
plex traits have been identified and reported in 
more than 2000 articles, many through highly 
reproducible genomewide association studies.6-8 
The cancer genetics community also organized 
several large efforts, including the Cancer Ge-
nome Atlas9 and the International Cancer Ge-
nome Consortium,10 in which the sequencing of 
genes obtained from both tumors and normal 
Figure 1. Variant Histogram from Mendelian Disease Testing of 15,000 Probands.
Shown are data for 5839 variants that have been found in patients with cardiomyopathy, hearing loss, RASopathies 
(i.e., developmental syndromes caused by germline mutations that alter the Ras subfamily), aortopathies, hereditary 
cancers, pulmonary disorders, skin disorders, and other genetic syndromes, as tested by the Laboratory for Molecu-
lar Medicine at Partners HealthCare. Shown at the top of the chart are the percentages of patients who carry fre-
quently observed pathogenic variants and patients who have variants that are rare or of uncertain significance.
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tissue has been implemented and resultant data 
deposited into databases to identify recurrent 
variants associated with different types of cancer. 
Most of these consortia and studies are focused 
on data obtained exclusively in the research set-
ting with predefined participating entities. To 
enable medical use of genetic discoveries, it is 
equally important to improve standards of data 
collection and sharing from genetic testing and 
define a systematic method for the clinical annota-
tion and interpretation of genomic and phenotypic 
variation.
To address these needs, three grants from the 
National Institutes of Health (NIH) were aligned 
with the NCBI ClinVar database under the col-
laborative Clinical Genome Resource (ClinGen) 
program (Fig. 2). The program was based in part 
on efforts of the earlier International Standards 
for Cytogenomic Arrays Consortium, which be-
gan collecting data on copy-number variants from 
chromosomal microarray testing in clinical cyto-
genetics laboratories in 2007, and was later ex-
panded to include data on sequence variants 
from clinical molecular laboratories.11 Consis-
tent with its mission, ClinGen is developing in-
terconnected community resources to improve 
our understanding of genomic variation and im-
prove its use in clinical care. ClinGen represents 
a strong partnership among public, academic, 
and private institutions that relies on collabora-
tion between the NIH and academic and com-
mercial laboratories operating in both the re-
search and clinical realms. ClinGen is also 
engaging numerous entities, including profes-
sional societies, to ensure that the resources that 
are produced meet the expectations of the com-
munity. Its goals are outlined in Table 1.
Launched in April 2013, the publicly accessi-
ble ClinVar database is a cornerstone of ClinGen. 
It serves as the primary site for deposition and 
retrieval of variant data and annotations.3 Vari-
ants and supporting evidence can be submitted 
by researchers, clinical laboratories, expert 
groups, clinicians, and patients (Fig. 3). Variants 
can also be reciprocally shared between ClinVar 
and locus-specific databases that may contain 
more detailed information specific to certain 
diseases and that are often maintained by dedi-
cated curators.12 For example, ClinGen-approved 
expert panels are depositing interpreted variants 
Figure 2. Clinical Genome Resource (ClinGen).
More information on ClinGen is available at www . clinicalgenome . org, and 
more information on ClinVar is available at www . ncbi . nlm . nih . gov/ clinvar.
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Launched in 2013 and supported by the National Institutes of 
Health, ClinGen is intended to be an authoritative central 
resource that defines the clinical relevance of genomic 
variants for use in precision medicine and research. 
ClinVar and Other Resources
ClinGen is developing several resources for the community. The first 
is ClinVar, which is a database at the National Center for Biotechnol-
ogy Information that archives information submitted about variants 
with medical relevance. It is an integral part of ClinGen and serves 
as its public portal for the deposition and retrieval of variants and 
the interpretation of their clinical significance. 
Goals
Share genomic and phenotypic data provided by clinicians, researchers,
and patients through centralized databases for clinical and research use
Standardize the clinical annotation and interpretation of genomic variants
Implement evidence-based expert consensus for curating genes and variants
Improve understanding of variation in diverse populations to realize
interpretation of genetic testing on a global scale
Develop machine-learning algorithms to improve the throughput of variant
interpretation
Assess the “medical actionability” of genes and variants
Structure and provide access to genomic knowledge for use in electronic 
health records ecosystems
Disseminate the collective knowledge and resources for unrestricted use
in the community
 Table 1. Goals of the Clinical Genome Resource (ClinGen).
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from databases such as CFTR2 (Clinical and 
Functional Translation of CFTR, which houses 
information about specific CFTR mutations),13
InSiGHT (variant database for the International 
Society for Gastrointestinal Hereditary Tumours),14
and PharmGKB (the Pharmacogenomics Knowl-
edge Base).15 As of May 4, 2015, ClinVar contained 
172,055 variant submissions across 22,864 genes 
(145,311 unique sequence and structural vari-
ants) from 314 submitters, including clinical and 
research laboratories, locus-specific databases, 
aggregate databases (Online Mendelian Inheri-
tance in Man [OMIM] and GeneReviews), expert 
consortia, professional organizations, health care 
providers (e.g., Sharing Clinical Reports Project, 
at www . sharingclinicalreports . org), and patients 
(e.g., Free the Data Campaign, at www . free-the
-data . org) (Table 2). More than 118,000 of the 
unique variants in ClinVar have clinical interpre-
tations, although 24,725 of those interpretations 
(21%) are variants of uncertain significance, 
which highlights the additional work to be done. 
Each time a laboratory submits variants for de-
position in ClinVar, the submission is analyzed 
to ensure that all variants are accurately named 
according to standardized variant nomencla-
ture16 and can be mapped to the human-genome 
reference sequence and that the terms used for 
assertions of clinical significance for mendelian 
disorders conform to those recently approved by 
the American College of Medical Genetics and 
Genomics.17 This standardization effort is impor-
tant for a robust submission and quality-control 
process. In addition, after deposition, each labo-
ratory receives a report of any differences in in-
terpretation between their submitted variants and 
those already existing in ClinVar.
In the past few years, it has become clear that 
Figure 3. Flow of Data through ClinGen.
Shown is the typical flow of information into ClinVar and ClinGenKB, a new database that is designed to allow for a flexible working en-
vironment for curation. Most variants are submitted by external sources and databases directly into ClinVar for immediate access by the 
community. Variants then flow into ClinGenKB to enable the resolution of differences in interpretation, as well as expert review of vari-
ants by the clinical-domain working groups that are shown. Additional sources of data and machine-learning algorithms may be brought 
into ClinGenKB to aid in the interpretive process. BIC denotes Breast Cancer Information Core, CFTR2 Clinical and Functional Transla-
tion of CFTR, InSiGHT the variant database for the International Society for Gastrointestinal Hereditary Tumours, OMIM Online Mende-
lian Inheritance in Man, and PharmGKB the Pharmacogenomics Knowledge Base.
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Variable Variants Genes
Submitter
Expert consortia and professional organizations
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 2,362 4
Clinical and Functional Translation of CFTR (CFTR2) 133 1
American College of Medical Genetics and Genomics (ACMG) 23 1
Clinical laboratories
International Standards for Cytogenomic Arrays Consortium Laboratories 14,441 >14,000
Partners HealthCare Laboratory for Molecular Medicine 12,092 302
GeneDx 11,176 613
Ambry Genetics 9,821 50
University of Chicago Genetic Services Laboratory 7,127 622
Emory University Genetics Laboratory 6,944 659
Sharing Clinical Reports Project for BRCA1 and BRCA2 2,147 2
Invitae 1,949 125
Laboratory Corporation of America (LabCorp) 1,390 160
ARUP Laboratories 1,374 10
Counsyl 1,136 108
Children’s Hospital of Eastern Ontario Molecular Genetics Diagnostic 
Laboratory
957 21
Blueprint Genetics 651 130
University of Washington CSER Program with Northwest Clinical Genomics Laboratory 646 80
University of Washington Collagen Diagnostic Laboratory 411 2
Children’s National Medical Center GenMed Metabolism Laboratory 317 1
Pathway Genomics 189 18
Baylor College of Medicine Medical Genetics Laboratories 178 12
Greenwood Genetic Center Diagnostic Laboratories 80 19
University of Pennsylvania School of Medicine Genetic Diagnostic Laboratory 68 1
Research programs and locus-specific databases
Breast Cancer Information Core (BIC) 3,734 2
Royal Brompton Hospital Cardiovascular Biomedical Research Unit 1,346 13
RettBASE 973 5
Muilu Laboratory, Institute for Molecular Medicine Finland 840 43
ClinSeq Project, National Human Genome Research Institute 425 36
Lifton Laboratory, Yale University 390 284
PALB2 Leiden Open Variation Database 242 2
Department of Ophthalmology and Visual Sciences, Kyoto University Hospital 171 59
Developmental Genetics Unit, King Faisal Specialist Hospital and Research 
Center, Saudi Arabia
101 102
Department of Zoology, M.V. Muthiah Government College, India 58 3
Aggregate databases
Online Mendelian Inheritance in Man (OMIM) 25,262 3,770
GeneReviews 4,000 488
Totals
Total variant submissions to ClinVar† 172,055
Total unique variants represented† 145,311
Total unique variants in ClinVar with clinical assertions† 118,169
Total genes in submissions with assertions
Genes in which variants are confined to the gene† 7,406
Genes in which copy-number variants span multiple genes† 22,864
*  All submissions from ClinGen-approved expert consortia and professional organizations are included even if submis-
sions include 50 or fewer variants.
†  Totals represent all submissions in ClinVar as of May 4, 2015, including smaller submissions that are not listed. 
Additional details are available at www . ncbi . nlm . nih . gov/ clinvar/ submitters.
Table 2. ClinVar Submitters Who Have Provided More Than 50 Variants with Medical Interpretations.*
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many genetic variants that have been reported in 
the literature to cause disease have been misin-
terpreted. Such errors have resulted from insuf-
ficient standards for defining the evidence re-
quired to link a variant to disease causation and 
our lack of information on common variation 
across many populations.18,19 The aggregation of 
data from many submitters that is enabled by 
ClinGen permits the identification of some vari-
ants that have been misinterpreted, as docu-
mented by different interpretations among sub-
mitters. Of the 118,169 unique variants with 
clinical interpretations, 12,895 (11%) have clini-
cal interpretations that have been submitted by 
more than one laboratory. Of those, 2,229 (17%) 
are interpreted differently by the submitters, 
with one- or two-step differences between any of 
three major levels: “pathogenic or likely patho-
genic,” “uncertain significance,” and “likely be-
nign or benign.” For example, one of the initial 
and ongoing sources of data in ClinVar is the 
OMIM database (containing nearly 25,000 vari-
ants), which catalogues representative pathogenic 
variants from published studies that define the 
role of a gene in disease, as well as the spectrum 
of variant types and phenotypes that are found 
for a gene.1 Now that ClinVar has already pro-
cessed many clinically curated submissions, we 
have identified 220 variants that have been de-
scribed in research studies and maintained in 
the public domain in OMIM as pathogenic and 
that now are being reinterpreted by clinical labo-
ratories as benign, likely benign, or of uncertain 
significance. Through ClinVar, the curators of 
OMIM now have a system that can more easily 
alert them to the need to reevaluate their records 
of gene–disease relationships. In addition, pa-
tients, clinicians, and clinical laboratories now 
have more robust public access to interpretations 
of genetic variants, which permits them to better 
use the information for clinical care decisions.
Of the ClinVar submissions from currently 
operating clinical laboratories and expert con-
sortia, 415 variants have different assertions of 
clinical significance of a level that is anticipated 
to have a differential effect on medical decision 
making (pathogenic or likely pathogenic vs. un-
certain significance, likely benign, or benign). 
Because a key goal of ClinGen is to resolve these 
differences, the American College of Medical Ge-
netics and Genomics (a ClinGen grantee) worked 
with members of the sequence and structural-
variant communities to develop new standards 
for interpreting genetic variants.17,20 ClinGen is 
now working with laboratories to facilitate adop-
tion of these new standards and openly share the 
basis of their assertions with respect to pathoge-
nicity. This collaboration has allowed laboratories 
to resolve differences in interpretation through 
expert consensus and application of these stan-
dardized methods. Furthermore, given the ex-
tremely fast pace at which genomic information 
is now being generated, the use of machine 
learning (which explores the development of al-
gorithms that can help to make predictions on 
data) or similar approaches for prioritizing vari-
ant curation, along with expert review, are criti-
cal for efficient turnaround of results. Thus, a 
resource that contains variants of uncertain 
significance and that can be targeted for further 
research through functional studies will enable 
improved understanding of genomic variation. 
This function, combined with the implementa-
tion of new standards for the interpretation of 
variants and the open sharing of assertions with 
respect to pathogenicity to identify differences, 
should eventually lead to a stronger reference 
database and to better health care.
ClinVar requests, but does not require, de-
tailed evidence to support any interpretation of 
clinical significance. One of the benefits of the 
ClinGen project, therefore, has been the devel-
opment of a tiered system to define the type of 
review by which any variant has been assessed 
(Fig. 4), as well as rules for aggregating interpre-
tations from multiple sources. In June 2015, the 
review status, which has always been represent-
ed graphically as colored stars, will be modified 
as follows: no stars if neither an assertion nor a 
documented method is provided, one star if 
methods are submitted for an interpretation, 
two stars if multiple groups with provided meth-
ods agree on the interpretation, three stars if the 
interpretation is provided by a ClinGen-approved 
expert panel, and four stars if the interpretation 
is endorsed by published practice guidelines. 
The review status is a field on which variants 
can be easily filtered when searching or down-
loading data from ClinVar, allowing specific 
subsets of variants to be selected on the basis of 
the level of review and consensus.
Overall, ClinGen-related working groups, with 
membership spanning more than 75 institutions, 
organizations, and commercial laboratories, have 
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been assembled to tackle many of the key chal-
lenges to achieving the goals of ClinGen, includ-
ing the establishment of standard procedures for 
evaluating genes, variants, genetic disorders, and 
phenotypes. For example, the accurate and de-
tailed collection of phenotype information is 
challenging yet critical to the assessment of hu-
man variation. ClinGen is taking a multipronged 
approach to this problem through support for, 
and interaction with, researchers, clinical labo-
ratories, clinicians, and patients. The ClinGen 
Phenotyping Working Group has chosen to use 
the Human Phenotype Ontology (www.human 
-phenotype-ontology.org) as its recommended 
standard for exchanging the phenotypes of pa-
tients, though other ontologies are also sup-
ported. Tools for the standardized collection of 
rare-disease phenotypes include PhenoTips21 and 
PhenoDB22 in addition to a phenotyping survey 
designed for patients in the ClinGen patient regis-
try (called GenomeConnect), as described below.
The ClinGen Gene Curation Working Group 
has developed standards for assigning the level 
of evidence supporting a gene–disease relationship 
(www . clinicalgenome . org/ knowledge-curation/ 
gene-curation), which will be used by expert 
groups in different disease areas. This framework 
is particularly relevant as larger gene panels are 
introduced into genetic testing. Such panels may 
include genes for which the strength of the data 
underlying the association between a specific 
variant or variants in a specific gene and disease 
is limited. A user interface is being developed to 
support expert curation of genes and variants 
within a new database called ClinGenKB, allow-
ing a flexible working environment for curation. 
Variants that are deposited into ClinVar will be 
accessible to curators working in ClinGenKB to 
enable expert review of all variants and resolu-
tion of conflicting interpretations. ClinGen has 
launched a growing number of clinical-domain 
working groups, with the initial set covering 
cardiovascular disease, hereditary cancer, so-
matic cancer, metabolic disease, and pharma-
cogenomics, with others in the planning stages 
(Fig. 3). The ClinGen Actionability Working 
Group is identifying which genes are associated 
with specific therapeutic or surveillance inter-
ventions in persons who do not yet have symp-
toms of genetic disease. The group has also de-
veloped a system for semiquantitative assessment 
of actionability that includes disease severity and 
likelihood, as well as the nature and efficacy of 
interventions. Additional working groups are fo-
cusing on new informatics approaches to variant 
assessment, integration with electronic health rec-
ords, and outreach to patients through Genome-
Connect, which allows patients to upload genetic 
test results and provide direct phenotypic data to 
the project. In addition, GenomeConnect enables 
a system to connect patients with laboratories, 
research studies, and one another, providing 
a robust and critical link to the broader com-
munity.
It is likely that the hypothetical case that is 
presented in the introduction to this article has 
already happened, given that each element of the 
story has occurred repeatedly. Patients have been 
receiving clinical genetic test results for hyper-
trophic cardiomyopathy for more than 10 years, 
and the American Heart Association has recom-
mended the use of those results for dictating the 
clinical care of family members.23 The interpre-
tation of many variants in genes associated with 
hypertrophic cardiomyopathy that have been re-
ported as pathogenic has been challenged,24 and 
laboratories have had to revise their interpreta-
tions and communicate those revisions to pa-
tients.25 Fortunately, the ClinVar database is be-
Figure 4. Review Levels Annotated in ClinVar.
Variants with assertions are rated according to the source and level of re-
view for each submitted variant assertion. Submitters must comply with re-
quirements (www.ncbi.nlm.nih.gov/clinvar/docs/assertion_criteria) for a 
submission to be assigned one, three, or four stars. Two stars are automat-
ically assigned when multiple one-star submitted assertions are consistent. 
The distinction between submitters that have provided criteria and those 
that have not will begin in June 2015.
 Not applicable
No stars
Practice
Guideline
Expert Panel
Multisource Consistency
Single Submitter — Criteria Provided
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ing increasingly used by clinical laboratories, 
physicians, and even patients, with more than 
5000 hits per day. Faced with the challenge of 
regulating next-generation sequencing tests, the 
Food and Drug Administration is now looking 
to ClinGen to provide a possible resource for the 
clinical interpretation of genetic variation.26 
With a system in place to support the open shar-
ing of clinically interpreted genomic data, we 
are now poised to shepherd in a new era of 
transparency and advancement in genomic sci-
ence that has the potential to improve how ge-
nomic information will inform the enhanced 
clinical care of patients.
ClinGen is funded by the National Human Genome Research 
Institute, with additional funding from the Eunice Kennedy 
Shriver National Institute of Child Health and Human Develop-
ment and the National Cancer Institute (U41 HG006834, U01 
HG007436, U01 HG007437, HHSN261200800001E). ClinVar is 
supported by the Intramural Research Program of the NIH, Na-
tional Library of Medicine.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank all the contributing members of ClinGen at www 
. clinicalgenome . org/ about/ people, Scott Goehringer for his as-
sistance in the development of the original Figure 1, and Steven 
Harrison for ClinVar data analysis.
From Harvard Medical School and Brigham and Women’s Hos-
pital and Partners HealthCare — all in Boston (H.L.R.); Univer-
sity of North Carolina, Chapel Hill ( J.S.B., J.P.E.); National Hu-
man Genome Research Institute, National Institutes of Health 
(NIH) (L.D.B., E.M.R.), National Center for Biotechnology In-
formation, National Library of Medicine, NIH (M.J.L., D.R.M., 
S.T.S.), and American College of Medical Genetics and Genom-
ics (M.S.W.) — all in Bethesda, MD; Stanford University School 
of Medicine, Stanford (C.D.B.), and University of California, 
San Francisco, San Francisco (R.L.N.) — both in California; 
Geisinger Health System, Danville, PA (D.H.L., C.L.M.); and 
Baylor College of Medicine, Houston (S.E.P.). Address reprint 
requests to Dr. Rehm at the Laboratory for Molecular Medicine, 
Partners HealthCare Personalized Medicine, 65 Landsdowne 
St., Cambridge, MA 02139-4232, or at  hrehm@ partners . org.
This article was published on May 27, 2015, at NEJM.org.
1. McKusick-Nathans Institute of Genetic Medicine, Johns 
Hopkins Medicine. Online Mendelian Inheritance in Man 
(OMIM) (http://omim .org).
2. 1000 Genomes Project. 1000 Genomes: a deep catalog of 
human genetic variation (http://www .1000genomes .org).
3. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive 
of relationships among sequence variation and human pheno-
type. Nucleic Acids Res 2014; 42: D980-D985.
4. National Research Council. Sharing publication-related data 
and materials: responsibilities of authorship in the life sciences. 
Washington, DC: National Academies Press, 2003.
5. Chanock SJ, Manolio T, Boehnke M, et al. Replicating geno-
type-phenotype associations. Nature 2007; 447: 655-60.
6. Hindorff LA, MacArthur J, Morales J, et al. A catalog of pub-
lished genome-wide association studies (http://www .genome 
.gov/ gwastudies).
7. Manolio TA. Bringing genome-wide association findings 
into clinical use. Nat Rev Genet 2013; 14: 549-58.
8. Paltoo DN, Rodriguez LL, Feolo M, et al. Data use under the 
NIH GWAS data sharing policy and future directions. Nat Genet 
2014; 46: 934-8.
9. National Cancer Institute, National Human Genome Re-
search Institute. The Cancer Genome Atlas (http:// 
cancergenome .nih .gov).
10. International Cancer Genome Consortium home page 
(https:/ / icgc .org).
11. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: 
chromosomal microarray is a first-tier clinical diagnostic test 
for individuals with developmental disabilities or congenital 
anomalies. Am J Hum Genet 2010; 86: 749-64.
12. den Dunnen JT, Sijmons RH, Andersen PS, et al. Sharing 
data between LSDBs and central repositories. Hum Mutat 2009; 
30: 493-5.
13. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the dis-
ease liability of variants in the cystic fibrosis transmembrane 
conductance regulator gene. Nat Genet 2013; 45: 1160-7.
14. Thompson BA, Spurdle AB, Plazzer J-P, et al. Application of 
a 5-tiered scheme for standardized classification of 2,360 
unique mismatch repair gene variants in the InSiGHT locus-
specific database. Nat Genet 2014; 46: 107-15.
15. Thorn CF, Klein TE, Altman RB. PharmGKB: the Pharma-
cogenomics Knowledge Base. Methods Mol Biol 2013; 1015: 311-
20.
16. Human Genome Variation Society. Nomenclature for the de-
scription of sequence variants, 2013 (http://www .hgvs .org/ 
mutnomen).
17. Richards S, Aziz N, Bale S, et al. Standards and guidelines 
for the interpretation of sequence variants: a joint consensus 
recommendation of the American College of Medical Genetics 
and Genomics and the Association for Molecular Pathology. 
Genet Med 2015; 17: 405-23. 
18. Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for 
severe childhood recessive diseases by next-generation sequenc-
ing. Sci Transl Med 2011; 3: 65ra4.
19. Berg JS, Adams M, Nassar N, et al. An informatics approach 
to analyzing the incidentalome. Genet Med 2013; 15: 36-44.
20. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, 
South ST. American College of Medical Genetics standards and 
guidelines for interpretation and reporting of postnatal consti-
tutional copy number variants. Genet Med 2011; 13: 680-5.
21. Girdea M, Dumitriu S, Fiume M, et al. PhenoTips: patient 
phenotyping software for clinical and research use. Hum Mutat 
2013; 34: 1057-65.
22. Hamosh A, Sobreira N, Hoover-Fong J, et al. PhenoDB: a new 
Web-based tool for the collection, storage, and analysis of phe-
notypic features. Hum Mutat 2013; 34: 566-71.
23. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guide-
line for the diagnosis and treatment of hypertrophic cardiomy-
opathy: executive summary: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force 
on Practice Guidelines. J Am Coll Cardiol 2011; 58: 2703-38.
24. Andreasen C, Nielsen JB, Refsgaard L, et al. New popula-
tion-based exome data are questioning the pathogenicity of pre-
viously cardiomyopathy-associated genetic variants. Eur J Hum 
Genet 2013; 21: 918-28.
25. Aronson SJ, Clark EH, Varugheese M, Baxter S, Babb LJ, 
Rehm HL. Communicating new knowledge on previously re-
ported genetic variants. Genet Med 2012; 14: 713-9.
26. Food and Drug Administration. Optimizing FDA’s regula-
tory oversight of next generation sequencing diagnostic tests 
— preliminary discussion paper. January 18, 2015 (http://
www .fda .gov/ downloads/ medicaldevices/ newsevents/ 
 workshopsconferences/ ucm427869 .pdf).
DOI: 10.1056/NEJMsr1406261
Copyright © 2015 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at Ghent University Library on October 8, 2020. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
